Skip to main content
Premium Trial:

Request an Annual Quote

GE Healthcare to Acquire Biacore for $390M

NEW YORK, June 20 (GenomeWeb News) - GE Healthcare, through its wholly owned subsidiary GE Medical Holding AB, today announced its intention to acquire Biacore International for approximately SEK2.9 billion ($390 million) in order to expand its worldwide protein research footprint.
 
GE Healthcare will initiate a tender offer to acquire all of the outstanding shares of Biacore for SEK330 per share, and the offer is expected to commence by July 10 and end on August 10. Biacore's board of directors has unanimously recommended accepting the offer, the companies said.
 
Shareholders in Biacore hold approximately 41.3 percent of the company. Pfizer Health is the largest shareholder, holding approximately 4 million shares, or 41 percent of the company, and has "irrevocably and unconditionally committed to accept the offer," the companies said. Management and members of Biacore's board of directors together hold approximately 0.3 per cent of the company, and have also committed to accept the offer.
 
Biacore, based in Uppsala, Sweden, trades on the Stockholm Stock Exchange under the symbol "BCOR." The offer of SEK330 per share represents a premium of 35 percent relative to Biacore's volume weighted average share price of SEK245 on the SSE during the month ended June 19; and a premium of 17 percent relative to the closing share price of SEK282 on June 19, the companies said.
 
GE Healthcare does not currently own any shares in Biacore. The offer will be financed by cash funds contributed by GE Medical Systems Information Technologies, which is GE Medical Holding AB's immediate parent company.
 
Biacore sells instrumentation and reagents for analyzing protein-protein interactions for biomedical and drug-discovery research. The combination of Biacore with GE Healthcare will create a broad offering of tools for protein research, the companies said.
 
"Life sciences is a key area of growth for GE Healthcare, and Biacore is highly complementary and synergistic with our existing protein sciences business," Joe Hogan, president and CEO of GE Healthcare, said in a statement. "Expanding on GE Healthcare's expertise in this area supports our objective of helping to diagnose and treat disease earlier."
 
Erik Wallden, CEO and President of Biacore, said in a statement, "As a result of today's transaction, Biacore will be able to benefit from the additional technical and commercial resources of GE Healthcare to accelerate its growth and further expand our opportunities in protein research."
 
Biacore employs approximately 300 people worldwide, and operates R&D and manufacturing facilities in Uppsala, where GE Healthcare's Life Sciences business is also headquartered. Upon completion of the tender offer, GE Healthcare intends to combine Biacore with GE Healthcare Life Sciences to create a center of excellence in protein science in Uppsala, the companies said.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.